A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis.
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
30
07
2020
accepted:
10
11
2020
pubmed:
24
11
2020
medline:
22
6
2021
entrez:
23
11
2020
Statut:
ppublish
Résumé
The objective of this work was to characterize outcomes of patients with isolated brain metastases managed with local therapy followed by immune checkpoint inhibitor (ICI) therapy. Patients from four medical centers were included if they presented with isolated brain metastases treated with local therapy and received adjuvant treatment with ICIs. Eleven patients with median size of largest brain metastasis of 3.9 cm, treated with surgical resection (n = 8) and/or stereotactic radiosurgery (SRS; n = 6), were included. Ipilimumab/nivolumab was the adjuvant ICI used in four patients, of whom one recurred (25%) and none died, compared with three of seven (43%) who recurred and two of seven (29%) who died following adjuvant treatment with ICI monotherapy. All recurrences were intracranial. Patients with isolated brain metastases treated with surgery or SRS appeared to benefit from adjuvant ICI therapy, particularly with combination therapy. Recurrences in this setting appear to largely occur intracranially.
Sections du résumé
BACKGROUND
The objective of this work was to characterize outcomes of patients with isolated brain metastases managed with local therapy followed by immune checkpoint inhibitor (ICI) therapy.
MATERIALS AND METHODS
Patients from four medical centers were included if they presented with isolated brain metastases treated with local therapy and received adjuvant treatment with ICIs.
RESULTS
Eleven patients with median size of largest brain metastasis of 3.9 cm, treated with surgical resection (n = 8) and/or stereotactic radiosurgery (SRS; n = 6), were included. Ipilimumab/nivolumab was the adjuvant ICI used in four patients, of whom one recurred (25%) and none died, compared with three of seven (43%) who recurred and two of seven (29%) who died following adjuvant treatment with ICI monotherapy. All recurrences were intracranial.
CONCLUSION
Patients with isolated brain metastases treated with surgery or SRS appeared to benefit from adjuvant ICI therapy, particularly with combination therapy. Recurrences in this setting appear to largely occur intracranially.
Identifiants
pubmed: 33225544
doi: 10.1002/onco.13608
pmc: PMC7930401
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e505-e507Subventions
Organisme : NCI NIH HHS
ID : R01 CA227481
Pays : United States
Organisme : NCI NIH HHS
ID : K23 CA204726
Pays : United States
Informations de copyright
© 2020 AlphaMed Press.
Références
Ann Oncol. 2016 Dec;27(12):2288-2294
pubmed: 27637745
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
Lancet. 2020 May 16;395(10236):1558-1568
pubmed: 32416781
Lancet Oncol. 2018 May;19(5):672-681
pubmed: 29602646
Pigment Cell Melanoma Res. 2019 Jul;32(4):553-563
pubmed: 30767428
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131
J Clin Oncol. 2019 Jan 1;37(1):52-60
pubmed: 30407895
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551